Skip to Content Contact Us
Appointment of special advisor for M&A and exits

Goldman Bio is proud to announce that Mr. David Gitlin is joining the company as a special advisor to the management and board on issues of M&A and exit transactions.

David Gitlin

David Gitlin is a leading lawyer and expert with rich international experience in business and corporate law, with a focus on mergers and acquisitions, capital financing, venture capital, technology contracting and licensing, and securities transactions.   He is a partner in the prominent Law Firm of Royer Cooper Cohen Braunfeld LLC, and for the past 13 years he has been ranked as a leading M&A lawyer by Chambers and Partners International, which is considered one of the most prestigious guides to outstanding lawyers globally. To date he has successfully handled more than 300 M&A transactions, including over 100 exits and over 100 international transactions in 18 different countries. His largest transaction was valued at $ 4 Billion. He has significant experience in selecting and working with investment bankers and has conducted approximately 100 buy-side and sell-side transactions through them.  He has strong ties to Israel and works tirelessly to strengthen Israeli-US trade relations in general and with Philadelphia, his city of residence, in particular, and in promoting Israeli companies. Mr. Gitlin has been honored by the Mayors of Tel Aviv and Philadelphia for these activities. Mr. Gitlin’s expertise and track record make him extremely suitable for his role as a special advisor to Goldman Bio in these matters.  Goldman Bio has created an avenue for establishing limited partnerships whose area of activity is R&D. This is a significant innovation for those seeking to invest in technology, which is creating a channel for establishing publicly available investment partnerships for a wide range of investors seeking to participate in the success of the Israeli high-tech industry in general, and in R&D in particular. The purpose of the Goldman Bio’s Limited Partnership is to promote the research and development of its portfolio companies, turning them into independent and professionally managed companies, built on technologies with significant commercial potential and high economic value. Goldman Bio’s controlling shareholder, Dr. Gil Pogozelich, warmly welcomes Mr. Gitlin’s consent to join Goldman Bio in order to realize its vision by accompanying its subsidiaries in achieving successful exits.


Back top top